Transdermal testosterone delivery: Comparison between scrotal and nonscrotal delivery systems

Pharmaceutical Development and Technology

Volumn 4, Issue 3, 1999, Pages 405-414

  Lin, Senshang ^a   Xing, Qing Feng ^a   Chien, Yie W ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Nonscrotal; Scrotal; Swine; Testosterone; Transdermal

Indexed keywords

TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; MALE; NONHUMAN; PRIORITY JOURNAL; SCROTUM; SKIN PERMEABILITY; SWINE; TESTOSTERONE BLOOD LEVEL; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; KINETICS; MALE; SCROTUM; SKIN ABSORPTION; SWINE; SWINE, MINIATURE; TESTOSTERONE;

EID: 0032800477     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.1081/PDT-100101376     Document Type: Article

References (26)

1. P. J. Snyder and D. A. Lawrence, Treatment of male hypogonadism with testosterone enanthate, J. Clin. Endocrinol. Metab., 51(6), 1335-1339 (1980).
2. R. Z. Sokol, A. Palacios, L. A. Campfield, C. Saul, and R.S. Swerdloff, Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men, Fertil. Steril., 37(3), 425-430 (1982).
3. H. M. Behre and E. Nieschlag, Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester, J. Clin. Endocrinol. Metab., 75(5), 1204-1210 (1992).
4. D. J. Handelsman, A. J. Conway, and L. M. Boylan, Pharmacokinetics and pharmacodynamics of testosterone pellets in man, J. Clin. Endocrinol. Metab., 71(1), 216-222 (1990).
5. S. G. Johnsen, E. P. Bennett, and V. G. Jensen, Therapeutic effectiveness of oral testosterone, Lancet, 2(7895), 1473-1475 (1974).
6. J. A. Cantrill, P. Dewis, D. M. Large, M. Newman, and D. C. Anderson, Which testosterone replacement therapy? Clin. Endocrinol., 21(2), 97-107 (1984).
7. F. Franchi, M. Luisi, and P. M. Kicovic, Long term study of oral testosterone undecanoate in hypogonadal males, Int. J. Androl., 1, 270-278 (1978).
8. C. A. Stuenkel, R. E. Dudley, and S. S. Yen, Sublingual administration of testosterone-hydroxypropyl-betacyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men, J. Clin. Endocrinol. Metab., 72(5), 1054-1059 (1991).
9. M. Bals-Pratsch, U. A. Knuth, Y. D. Yoon, and E. Nieschlag, Transdermal testosterone substitution therapy for male hypogonadism, Lancet, 2(8513), 943-946 (1986).
10. A. W. Meikle, N. A. Mazer, J. F. Moellmer, J. D. Stringham, K. G. Tolman, S. W. Sanders, and W. D. Odell, Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men, J. Clin. Endocrinol. Metab., 74(3), 623-628 (1992).
11. N. A. Mazer, W. E. Heiber, J. F. Moellmer, A. W. Meikle, J. D. Stringham, S. W. Sanders, K. G. Tolman, and W. D. Odell, Enhanced transdermal delivery of testosterone: a new physiological approach for androgen replacement in hypogonadal men, J. Controlled Release, 19(3), 347-362 (1992).
12. H. M. Behre, F. Oberpenning, and E. Nieschlag, Comparative pharmacokinetics of androgen preparations: application of computer analysis and simulation, in Testosterone - Action, Deficiency, Substitution (E. Nieschlag and H. M. Behre, eds.), Springer-Verlag, Berlin, 1990, pp. 115-135.
13. S. Bhasin, Clinical review 34: Androgen treatment of hypogonadal men, J. Clin. Endocrinol. Metab., 74(6), 1221-1225 (1992).
14. R. D. McClure, R. Oses, and M. L. Ernest, Hypogonadal impotence treated by transdermal testosterone, Urology, 37(3), 224-228 (1991).
15. Physicians' Desk Reference, 50th ed., Medical Economics Inc., Oradell, NJ, 1996.
16. Testoderm® (Testosterone Transdermal System) product information, ALZA Corporation, 1994.
17. Q. F. Xing, S. Lin, and Y. W. Chien, Transdermal testosterone delivery in castrated Yucatan minipigs: pharmacokinetics and metabolism, J. Controlled Release, 52(1-2), 89-98 (1998).
18. Y. W. Chien and K. H. Valia, Development of a dynamic skin permeation system for long-term permeation studies, Drug Dev. Ind. Pharm., 10, 575-599 (1984).
19. United States Pharmacopeia, 23rd ed., The United States Pharmacopeial Convention, Rockville, MD, 1995.
20. S. Lin and Y. W. Chien, A rapid and simple technique for serial or continuous collection of blood samples and intravenous administration of drugs to conscious swine, Contemp. Topics, 36(5), 58-61 (1997).
21. PCNONLIN User Guide, 4th ed., Statistical Consultants, Inc., Lexington, KY, 1992.
22. V. Srinivasan, D. Fikstad, N. A. Mazer, J. F. Moellmer, and C. D. Ebert, In vitro-in vivo correlation for the transdermal delivery of testosterone (abstract), Pharm. Res., 13(9), S-379 (1996).
23. Y. W. Chien, Novel Drug Delivery Systems, 2nd ed., Marcel Dekker, Inc., New York, 1992, pp. 338-344.
24. J. C. Findlay, V. A. Place, and P. J. Snyder, Transdermal delivery of testosterone, J. Clin. Endocrinol. Metab., 64(2), 266-268 (1987).
25. D. R. Brocks, A. W. Meikle, S. C. Boike, N. A. Mazer, N. Zariffa, P. R. Audet, and D. K. Jorkasky, Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose, J. Clin. Pharmacol., 36(8), 732-739 (1996).
26. Androderm® (Testosterone Transdermal System) product information, SmithKline Beecham Pharmaceuticals, 1995.